Literature DB >> 8095462

Positive chronotropic and inotropic responses to BRL 37344, a beta 3-adrenoceptor agonist in isolated, blood-perfused dog atria.

S Takayama1, Y Furukawa, L M Ren, Y Inoue, S Sawaki, S Chiba.   

Abstract

We investigated the chronotropic and inotropic responses to BRL 37344 (a beta 3-adrenoceptor agonist) and isoproterenol in isolated, blood-perfused dog atria. BRL 37344 (0.1-30 nmol) or isoproterenol (0.001-0.3 nmol) increased the sinus rate and contractile force dose dependently. BRL 37344 was 290 times less potent than isoproterenol to increase sinus rate and 140 times less potent to increase atrial force. Both propranolol and bisoprolol similarly inhibited the positive chronotropic and inotropic responses to BRL 37344 and isoproterenol dose dependently. ICI 118,551 (0.1 and 1 nmol) did not significantly affect the positive cardiac responses to BRL 37344 or isoproterenol. Neither imipramine nor tetrodotoxin significantly affected the positive cardiac responses to BRL 37344. These results suggest that the positive chronotropic and inotropic responses to BRL 37344 are mediated mainly by beta 1-adrenoceptors in the dog heart. It is unlikely that beta 3-adrenoceptors, as previously reported in adipose tissue or gastrointestinal smooth muscle, mediate chronotropic and inotropic responses in the normal dog heart.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8095462     DOI: 10.1016/0014-2999(93)90105-q

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  β(3) Receptors: Role in Cardiometabolic Disorders.

Authors:  Shraddha V Bhadada; Bhoomika M Patel; Anita A Mehta; Ramesh K Goyal
Journal:  Ther Adv Endocrinol Metab       Date:  2011-04       Impact factor: 3.565

2.  Beta 1- and beta 2-adrenoceptor antagonist activities of ICI-215001, a putative beta 3-adrenoceptor agonist.

Authors:  B Tesfamariam; G T Allen
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

Review 3.  Beta 3-adrenoreceptor regulation of nitric oxide in the cardiovascular system.

Authors:  An L Moens; Ronghua Yang; Vabren L Watts; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2010-02-23       Impact factor: 5.000

4.  Functional beta3-adrenoceptor in the human heart.

Authors:  C Gauthier; G Tavernier; F Charpentier; D Langin; H Le Marec
Journal:  J Clin Invest       Date:  1996-07-15       Impact factor: 14.808

5.  Adverse ventricular remodeling and exacerbated NOS uncoupling from pressure-overload in mice lacking the beta3-adrenoreceptor.

Authors:  An L Moens; Jordan S Leyton-Mange; Xiaolin Niu; Ronghua Yang; Oscar Cingolani; Elisabeth K Arkenbout; Hunter C Champion; Djahida Bedja; Kathleen L Gabrielson; Juan Chen; Yong Xia; Ashley B Hale; Keith M Channon; Marc K Halushka; Norman Barker; Floris L Wuyts; Pawel M Kaminski; Michael S Wolin; David A Kass; Lili A Barouch
Journal:  J Mol Cell Cardiol       Date:  2009-09-18       Impact factor: 5.000

6.  Inhibitory effects of SR 58611A on canine colonic motility: evidence for a role of beta 3-adrenoceptors.

Authors:  F De Ponti; M Cosentino; A Costa; M Girani; G Gibelli; L D'Angelo; G Frigo; A Crema
Journal:  Br J Pharmacol       Date:  1995-04       Impact factor: 8.739

7.  The preferential beta3-adrenoceptor agonist BRL 37344 increases force via beta1-/beta2-adrenoceptors and induces endothelial nitric oxide synthase via beta3-adrenoceptors in human atrial myocardium.

Authors:  C Pott; K Brixius; A Bundkirchen; B Bölck; W Bloch; D Steinritz; U Mehlhorn; R H G Schwinger
Journal:  Br J Pharmacol       Date:  2003-02       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.